Projects per year
Personal profile
Research Statement
The Stratified Medicine Group focuses on the following areas:
1) Characterisation of a molecular group in solid cancers that represents an innate immune response to DNA damage through the STING pathway.
2) Development of a biomarker for anti-angiogenic agents
3) Development of a biomarker for MEKK pathway activation
4) Identification of a prognostic biomarker for early prostate cancer
5) Development of new cell lines for pre-clinical modelling of ovarian and prostate cancer.
Other
Linked in Profile:
https://www.linkedin.com/in/profkennedy/
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Richard Kennedy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
R1300CNR: Future Medicines Institute
Scott, C. (PI), Bruce, I. (CoI), Burden, R. (CoI), Burrows, J. (CoI), Collins, B. (CoI), Harrison, T. (CoI), James, J. (CoI), Kennedy, R. (CoI), Lawler, M. (CoI), Longley, D. (CoI), Maguire, S. (CoI), Malinova, D. (CoI), Maule, A. (CoI), McCloskey, K. (CoI), McDade, S. (CoI), Salto-Tellez, M. (CoI), Savage, K. (CoI), Stitt, A. (CoI) & Williams, R. (CoI)
15/10/2024 → …
Project: Research
-
R3005CNR: Establishing a Precision Medicine Catapult Centre of Excellence in Northern Ireland
Salto-Tellez, M. (PI), Gonzalez de Castro, D. (CoI), James, J. (CoI), Kennedy, R. (CoI), McArt, D. (CoI) & Waugh, D. (CoI)
01/12/2017 → …
Project: Research
-
R2111CNR: Research Resource – A national digital pathology and image analysis platform for solid tumours, complemented by a comprehensive Clinical Fellowship programme in Molecular Pathology.
Salto-Tellez, M. (PI), James, J. (CoI), Kennedy, R. (CoI), Lawler, M. (CoI) & Waugh, D. (CoI)
09/06/2015 → …
Project: Research
-
R6416CNR: Phase 1B/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients
Van Schaeybroeck, S. (PI), Johnston, P. (CoI), Kennedy, R. (CoI), Lawler, M. (CoI), Longley, D. (CoI), Salto-Tellez, M. (CoI) & Wilson, R. (CoI)
01/08/2013 → …
Project: Research
-
R1005PMY: Artificial Intelligence Enables Clinical Decision Making in the Digital Healthcare Era
McArt, D. (PI), Kennedy, R. (CoI) & Salto-Tellez, M. (CoI)
12/02/2019 → 30/09/2020
Project: Research
-
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma
Baxter, M. A., Spender, L. C., Cairns, D., Walsh, S., Oparka, R., Porter, R. J., Bray, S., Skinner, G., King, S., Turbitt, J., Collinson, D., Miedzybrodzka, Z. H., Jellema, G., Logan, G., Kennedy, R. D., Turkington, R. C., McLean, M. H., Swinson, D., Grabsch, H. I. & Lord, S. & 3 others, , 13 May 2024, In: ESMO Open. 9, 5, 12 p., 103450.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)12 Downloads (Pure) -
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial
Scanlon, E., Lavery, A., Albraikat, M., Stevenson, L., Kennedy, C., Byrne, R., Walker, A., Mullan-Young, B., McManus, D. T., Virdee, P. S., Elhussein, L., Turbitt, J., Collinson, D., Miedzybrodzka, Z., Van Schaeybroeck, S., McQuaid, S., James, J. A., Craig, S. G., Blayney, J. K. & Petty, R. D. & 6 others, , Nov 2024, In: ESMO Open. 9, 11, 14 p., 103930.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Downloads (Pure) -
Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation
Griffin, D., Carson, R., Moss, D., Sessler, T., Lavin, D., Tiwari, V., Karelia, S., Kennedy, R., Savage, K. I., McDade, S., Carie, A., Pankovich, J., Bazett, M. & Van Schaeybroeck, S., 04 Sept 2024, (Early online date) In: Molecular Cancer Research. 14 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Downloads (Pure) -
USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF
Jurisic, A., Sung, P.-J., Wappett, M., Daubriac, J., Lobb, I. T., Kung, W.-W., Crawford, N., Page, N., Cassidy, E., Feutren-Burton, S., Rountree, J. S. S., Helm, M. D., O'Dowd, C. R., Kennedy, R. D., Gavory, G., Cranston, A. N., Longley, D. B., Jacq, X. & Harrison, T., 11 Apr 2024, In: Clinical and Translational Medicine. 14, 4, 22 p., e1648.Research output: Contribution to journal › Article › peer-review
Open AccessFile29 Downloads (Pure) -
Dual prognostic classification of triple-negative breast cancer by DNA damage immune response and homologous recombination deficiency
Stecklein, S. R., Barlow, W., Pusztai, L., Timms, K., Kennedy, R., Logan, G. E., Seitz, R., Badve, S., Gökmen-Polar, Y., Porter, P., Linden, H., Tripathy, D., Hortobagyi, G. N., Godwin, A. K., Thompson, A., Hayes, D. F. & Sharma, P., 16 Nov 2023, In: JCO Precision Oncology. 7, e2300197.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Citations (Scopus)
Prizes
-
Queen’s University of Belfast Vice Chancellor Award for Innovation
Kennedy, R. (Recipient), 2013
Prize: Prize (including medals and awards)
-
St Luke’s Medal for Cancer Research. Royal College of Medicine, Ireland
Kennedy, R. (Recipient), 2015
Prize: Prize (including medals and awards)
Press/Media
-
Targetable Immune Biology Found in Some Patients With Early-Stage Prostate Cancer
26/03/2018
1 Media contribution
Press/Media: Research
-
Behind the Science. 30 minute TV programme on Cancer Research at QUB/Almac
13/12/2017
1 Media contribution
Press/Media: Public Engagement Activities
-
High-tech disease profiling is the next stage in the fight against cancer
30/10/2017
1 Media contribution
Press/Media: Research
-
-
A visit to the Doctor in 2013. Public lecture.
10/10/2017
1 item of Media coverage
Press/Media: Public Engagement Activities
Impacts
-
Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation
Kennedy, R. (Participant), Harkin, P. (Participant), Johnston, P. (Participant), Hosey, A. (Participant), Miskelly, J. (Participant), Murray, M. (Participant), Quinn, J. (Participant), James, C. (Participant), Mulligan, J. (Participant), Daly, P. (Participant), Mullan, P. (Participant), Mussen, J. (Participant), McDermott, U. (Participant), Wilson, R. (Participant) & Longley, D. (Participant)
Impact: Health Impact, Quality of Life Impact